Dr. Curtis has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Pfizer, BMS, Crescendo, and Abbott, and (more than $10,000 each) from Roche/Genentech, UCB, Centocor, the Consortium of Rheumatology Researchers of North America, and Amgen.
Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis
Article first published online: 28 NOV 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 12, pages 1819–1828, December 2012
How to Cite
Curtis, J. R., Lanas, A., John, A., Johnson, D. A. and Schulman, K. L. (2012), Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res, 64: 1819–1828. doi: 10.1002/acr.21764
- Issue published online: 28 NOV 2012
- Article first published online: 28 NOV 2012
- Accepted manuscript online: 21 JUN 2012 09:14AM EST
- Manuscript Accepted: 7 JUN 2012
- Manuscript Received: 29 AUG 2011
- NIH. Grant Number: AR053351
- Agency for Healthcare Research and Quality. Grant Number: R01HS018517
- 1Gastrointestinal manifestations of rheumatoid arthritis. In: Asherson R, Font J, Ramos-Casals M, Rodes J, editors. Handbook of systemic autoimmune diseases. Vol. 8. Amsterdam: Elsevier; 2008. p. 109–17., , .
- 15Claims data analysis of dosing and cost of TNF antagonists. Am J Pharm Benefits 2010; 2: 351–9., , , , , .
- 22Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465–73., , , , .